资源类型：
Pubmed体系：
文章类型：
机构：
[1]West China Hospital of Sichuan University, Chengdu, China.
四川大学华西医院
[2]Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China.
ISSN：
摘要：
CD7 has been found to be a promising chimeric antigen receptor (CAR)-T cell target in several clinical trials. However, its expression on normal T cells poses additional challenges in CD7-directed CAR, such as complete fratricide, contamination with malignant cells, and immune suppression due to T-cell aplasia. By taking advantage of evolved affinity between ligand and receptor, we constructed a CD7-directed CAR with the extracellular domain of SECTM1, a natural ligand of CD7, as the recognition domain. SECTM1 CAR-T cells killed the majority of T cells with high CD7 expression in vitro. However, SECTM1 CAR-T cells with low or negative CD7 expression survived, expanded, and showed strong cytotoxicity to CD7-positive malignant cell lines and primary leukemic blasts from T-ALL and AML patients in vitro. It also exhibited efficacy in inhibiting xenograft tumor growth in vivo. More exploration is needed for clinical efficacy potential to CD7 positive patients.Copyright © 2023 American Society of Hematology.
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类
|
1 区
医学
小类
|
2 区
血液学
最新[2023]版：
大类
|
1 区
医学
小类
|
2 区
血液学
第一作者：
第一作者机构：
[1]West China Hospital of Sichuan University, Chengdu, China.
推荐引用方式(GB/T 7714)：
Wei Wenwen,Ma Haiyan,Yang Dong,et al.SECTM1-based CAR-T cells enriched with CD7low/negative subsets exhibit efficacy in CD7-positive malignancies[J].Blood advances.2023,doi:10.1182/bloodadvances.2022008402.
APA：
Wei Wenwen,Ma Haiyan,Yang Dong,Sun Bin,Tang Jie...&Zhao Xudong.(2023).SECTM1-based CAR-T cells enriched with CD7low/negative subsets exhibit efficacy in CD7-positive malignancies.Blood advances,,
MLA：
Wei Wenwen,et al."SECTM1-based CAR-T cells enriched with CD7low/negative subsets exhibit efficacy in CD7-positive malignancies".Blood advances .(2023)
